eISSN: 2449-8238
ISSN: 2392-1099
Clinical and Experimental Hepatology
Current issue Archive Manuscripts accepted About the journal Editorial board Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
3/2021
vol. 7
 
Share:
Share:
Original paper

Effect of abdominal fat distribution on severity of acute pancreatitis

Engin Beydogan
1
,
Semih Gulle
1
,
Celal Gezer
2
,
Banu Boyuk
3

  1. Van Education and Research Hospital, Turkey
  2. GOP Education and Research Hospital, Turkey
  3. Kartal Dr. Lutfi Kirdar Education and Research Hospital, Turkey
Clin Exp HEPATOL 2021; 7, 3: 264-269
Online publish date: 2021/10/11
Article file
- Effect.pdf  [0.11 MB]
Get citation
 
PlumX metrics:
 

Introduction

Acute pancreatitis (AP) is suddenly developing inflammation of the pancreas and is the gastrointestinal system disease requiring most frequent admission to intensive care from the emergency service, with increasing incidence worldwide [1-3]. The increase in AP incidence involves many factors such as obesity, alcohol, gallstones, medications, infection and trauma [4]. Obesity is a well-defined risk factor for acute pancreatitis. Increased visceral fat was shown to increase the proinflammatory environment experienced by patients.

In recent years, new scoring systems have been created, e.g. the Bedside Index Severity Acute Pancreatitis (BISAP), the Glasgow Prognostic Score (Imrie) and the Computed Tomography Severity Index (CTSI-Balthazar), for more appropriate determination of AP severity under emergency service conditions [5-7]. In this study, we aimed to research the correlation between abdominal fat distribution parameters measured with computed tomography (CT) and severity of acute pancreatitis.

Material and methods

Study population

The study included patients monitored for acute pancreatitis from January 2015 to December 2018. Data were retrospectively investigated. All patients had Acute Physiology and Chronic Health Evaluation (APACHE), Imrie and BISAP scores calculated within the first 24 hours of admission. The study included patients with AP diagnosis aged over 18 years. From these patients, those with traumatic pancreatitis diagnosis and pregnant cases were excluded from the study. Patient age, gender, height, weight, comorbid diseases and medications used were recorded. Patients had demographic characteristics, laboratory results, pulmonary radiography and abdominal CT results evaluated and BISAP, Imrie and Balthazar scores calculated [8, 9].

Definition of acute pancreatitis severity

Patients with AP diagnosis were classified as having mild, moderate or severe AP (SAP) according to the revised Atlanta criteria from 2012 along with AP clinical, radiological and anatomical findings [10]. Cases of patients with organ failure within 48 hours after attendance at hospital and/or dead patients were considered as severe AP [11]. Additionally, cases of patients without organ failure but with development of local severe complications such as necrosis or abscess were considered as severe AP [10]. Organ failure status was calculated using the Marshall score. In this scoring, if patients receive ≥ 2 points, they are accepted as having developed organ failure [12]. All patients with AP diagnosis were monitored and treated according to the evidence-based AP management guidelines of the International Association of Pancreatology and American Pancreatic Association (IAP/APA) [13].

Assessment of abdominal fat tissue distribution with CT: With division of abdominal tissue, advanced image processing analysis software (INFINIT Xelis, v 1.0.6.3) was used to calculate individual abdominal fat distribution parameters from CT screening with measurements performed from –50 to –250 HU between vertebrae L2-L3.

Power analysis

A statistical power analysis was performed for sample size estimation, based on data from the published study by Natu et al. (N = 252) [14]. The effect size in this study was 0.3, considered to be extremely large using Cohen’s (1988) criteria. With an α = 0.05 and power = 0.80, the projected sample size needed with this effect size (GPower 3.1.9.4 software) is approximately N = 64+ for this simplest between/within group comparison. Thus, our proposed sample size of n = 170 will be more than adequate for the main objective of this study and should also allow for expected attrition and our additional objectives of controlling for possible subgroup analysis.

Statistical analyses

Analysis of data used the program SPSS Statistics 21.0 (IBM Corporation, Armonk, New York, USA). Since there were no patients suitable for the diagnosis of severe pancreatitis in our study, the patients were grouped as mild and moderate AP. Normal distribution of data was checked with the Kolmogorov-Smir-nov test. Descriptive statistics are given as mean ± standard deviation (SD), while nominal variables are given as case numbers and percentages (%). Continuous variables with normal distribution were compared with the Student t test, while continuous variables without normal distribution were compared with the Mann-Whitney U test. The χ2 or Fisher’s exact test was used to compare categoric variables. The Mann-Whitney U test was used with Monte Carlo simulation technique to compare two independent groups with each other according to quantitative data. Spearman’s rho test was used to examine the correlations of variables with each other. Correlation between APACHE, Imrie, and Balthazar scores and abdominal fat distributions was made with a bipartial correlation analysis. The statistical significance level for the obtained data was interpreted with the p value. P < 0.05 was accepted as statistically significant.

Results

The mean age in the study was 58.7 ±18.3 years, with a total of 174 patients, 107 females (61.5%) and 67 males (38.5%). Of patients included in the study, 142 (81.6%) had mild and 32 (19.4%) had moderate AP. Among all patients, 114 (65.5%) were identified to have biliary pancreatitis, and this was identified more frequently in patients with moderate AP (p < 0.001) (Table 1). Moderate AP patients had longer duration of hospital stay, and higher Imrie and Balthazar scores (p < 0.001). Additionally, no significant differences were identified between the groups in terms of Apache and BISAP scores (Table 1). When the groups were assessed in terms of visceral fat tissue, subcutaneous fat tissue and total fat tissue ratios, no significant difference was identified (p > 0.05).

Table 1

Clinical and laboratory characteristics of patients

VariableMild AP (n = 142)
Mean ±SD
Moderate AP (n = 32)
Mean ±SD
P value
Age (years)58.7 ±18.4158.03 ±17.730.855
Gender (M/F)90/5217/150.101
Etiology (biliary/nonbiliary)87/5527/5< 0.001
MortalityNone3< 0.001
APACHE score4.13 ±2.954.77 ±3.200.295
Median (IQR)Median (min./max.)P value
Hospitalization delay (days)5 (4)7 (10)< 0.001
Imrie score1 (2)2 (2)< 0.001
BISAP score1 (1)1 (2)0.007
Balthazar score1 (2)3 (2)< 0.001
VAT (cm2)142.83 (130.27)146.80 (137.06)0.178
SAT (cm2)169.79 (134.07)132.99 (117.24)0.166
Total fat area (cm2)327.39 (203.54)292.11 (171.55)0.099
VSR0.840 (0.489)0.978 (0.772)0.863
VTR0.460 (0.215)0.494 (0.188)0.961
STR0.549 (0.211)0.506 (0.188)0.961

[i] Data are shown as mean ±SD; Wilcoxon signed ranks test (Monte Carlo); VAT – visceral tissue total surface area, SAT – subcutaneous tissue total surface area, VSR – visceral to subcutaneous fat area ratio, VTR – visceral to total fat area ratio, STR – subcutaneous to total fat area ratio, BISAP – Bedside Index Severity Acute Pancreatitis score; Imrie, Glasgow Prognostic Score

When patients are assessed in terms of complication development, 2 out of 11 patients developing systemic complications were identified to develop simultaneous local complications. Patients developing systemic complications were found to be older and have higher BISAP scores (Table 2). Patients developing local complications had a higher Balthazar score than those who did not develop local complications (p < 0.001) (Table 2). No significant differences were identified between patients developing and not developing complications in terms of visceral adipose tissue (VAT) volume, subcutaneous fat tissue area (SFA) and total fat tissue area (TFA) measurements, visceral to subcutaneous fat tissue ratio (VSR), visceral to total fat tissue area ratio (VTR) or subcutaneous to total fat tissue area ratio (STR).

Table 2

Comparison of groups with absence of systemic and local complications

VariableSystemic complicationsP valueLocal complicationsP value
Present
(n = 11)
Mean ±SD
Absent
(n = 163)
Mean ±SD
Present
(n = 10)
Mean ±SD
Absent
(n = 164)
Mean ±SD
Age (years)77.64 ±13.9557.29 ±17.80< 0.00159.30 ±15.3758.54 ±18.440.902
APACHE score7.27 ±2.374.04 ±2.920.0016.10 ±4.064.13 ±2.890.167
Imrie score3.09 ±1.511.17 ±1.0502.3 ±1.491.23 ±1.130.053
Median (IQR)Median (IQR)P valueMedian (IQR)Median (IQR)P value
Hospitalization delay (days)10 (14)5 (4)0.1117 (8)5 (3)0.04t
BISAP score2 (1)1 (1)< 0.0011 (2)1 (1)0.217
Balthazar score3 (4)2 (3)0.2024 (1)2 (3)< 0.001t
VFA (cm2)105.18 (78.24)144.01 (129.43)0.397213.06 (112.14)141.81 (128.59)0.842
SFA (cm2)112.36 (117.93)166.47 (129.16)0.294123.57 (94.25)166.47 (132.71)0.021
TFA (cm2)241.47 (211.57)327.31 (184.89)0.108341.98 (183.37)326.40 (199.74)0.132
VSR0.874 (0.276)0.882 (0.777)0.0371.663 (2.073)0.858 (0.720)0.066
VTR0.466 (0.820)0.473 (0.217)0.0070.610 (0.303)0.464 (0.199)0.60
STR0.534 (0.082)0.536 (0.212)0.0070.390 (0.303)0.540 (0.197)0.60

[i] Data are shown as mean ±SD. tIndependent samples t test (bootstrap). VFA – visceral tissue total surface area, SFA – subcutaneous tissue total surface area, total surface area, VSR – visceral to subcutaneous fat area ratio, VTR – visceral to total fat area ratio, STR – subcutaneous to total fat area ratio, BISAP – Bedside Index Severity Acute Pancreatitis score, Imrie, Glasgow Prognostic Score

In our study, a weak positive correlation was identified for VAT and VSR with APACHE scores (r = 0.256 and r = 0.252, respectively, p < 0.001) (Table 3). A weak positive correlation was identified for VTR and VSR ratios with BISAP scores (r = 0.266 and r = 0.277, respectively, p < 0.001) (Table 3). No significant correlation was identified between clinical scoring systems and pancreatitis severity.

Table 3

Correlations between acute pancreatitis severity scores and abdominal fat tissue measurements

VariableAP severity scores
APACHEImrieBISAP
rprprp
VFA0.256< 0.0010.271< 0.0010.1990.009
SFA0.0110.8890.0110.8890.0940.221
VTR0.250< 0.0010.1120.1440.266< 0.001
STR0.2300.0020.2040.0080.261< 0.001
VSR0.252< 0.0010.2260.0030.277< 0.001

[i] Partial correlation test, r – correlation coefficient AP – acute pancreatitis, VFA – visceral tissue total surface area, SFA – subcutaneous tissue total surface area, VSR – visceral to subcutaneous fat area ratio, VTR – visceral to total fat area ratio, STR – subcutaneous to total fat area ratio, BISAP – Bedside Index Severity Acute Pancreatitis score, Imrie, Glasgow Prognostic Score

Discussion

Obesity is a well-determined risk factor for AP. Increased visceral fat was shown to increase the proinflammatory environment experienced by patients. In our study, we did not identify a correlation of visceral fat tissue surface area or any abdominal fat tissue area ratios, measured with CT and assessed as an objective measure of obesity, with the severity of AP.

Acute pancreatitis may have variable clinical status from a mild degree of inflammation of the pancreas to severe progressive pancreatic necrosis. In 80% of patients the clinical course is self-limiting and they improve without recurrence. For nearly 15% of patients, pancreatic necrosis requiring a few weeks of hospital stay. Of patients developing necrosis, nearly 35% develop multiorgan failure while 20% develop infected pancreatic necrosis. Developing multiorgan failure and infected pancreatic necrosis are associated with mortality rates of 6-23% [15, 16].

Early diagnosis of severe AP and identification of patients requiring aggressive treatment in the early period have vital importance. The Atlanta criteria have been used to determine AP severity and treatment planning since 1992. The IAP/APA diagnostic and treatment guidelines recommend initial hemodynamic status assessment and stabilization of AP patients in the emergency service [13]. In the second stage, it is recommended that patients be assessed with an appropriate scoring system without losing time [17]. There are many scoring systems, e.g. Ranson, APACHE II, BISAP, Imrie, Balthazar, and PANC3, to determine the severity of AP [9, 10, 18].

In the literature, there are many studies investigating the correlation between age and AP mortality. In spite of a low rate of increase in the incidence of AP in recent years, the incidence of severe AP has increased at a relatively high rate. The most important reason for this increase was shown to be the increase in mean patient age [19, 20]. A study by Gardner et al. of 70 AP patients found that the mortality rate was significantly high among patients over 70 years of age (21.4% vs. 7.1%) (OR = 3, p = 0.028) [21]. A retrospective study by Wang et al. found being ≥ 72 years old was predictive for organ failure in 393 AP patients [22]. In our study, the mean age of patients with AP diagnosis was 58.7 ±18.3 years, and it is considered important that the age variable does not affect the correlation between obesity and pancreatitis, which we aimed to assess in this study.

Another explanation for the relationship between abdominal obesity and the development of severe AP is that obese patients have a chronic proinflammatory state that may predispose to a greater inflammatory response when AP occurs. The evidence supporting this inflammatory response hypothesis comes from two different studies showing increased levels of C-reactive protein and/or proinflammatory cytokines (IL-1β, IL-6 and IL-8) in obese patients with AP compared to non-obese patients [23, 24].

A meta-analysis of five studies showed that obese patients had a 2.9-fold (OR: 2.9, 95% CI: 1.8-4.6) increased risk for severe AP and a 2.1-fold (OR: 2.1, 95% CI: 1.0-4.8) increased risk for AP with a fatal outcome [23].

There is a strong correlation between AP severity and obesity [25, 26]. A study by Katuchova et al. reported that patients with body mass index (BMI) > 30 kg/m2 had more local and systemic complications and that obesity was a significant negative predictor for mortality [27]. Taguchi et al. emphasized that like those who are overweight, very thin people were at risk in terms of acute pancreatitis [28]. A study by Krishna et al. found that morbidly obese AP patients spent longer in hospital; these patients developed more organ failure and had higher mortality (OR: 1.6, 95% CI: 1.3-1.9) [29]. The reason for this is thought to be that patients with high BMI have an increased pancreatic fat amount which is associated with a direct toxic effect on pancreas parenchyma and delayed healing [26, 27]. Proinflammatory cytokines released in excess amounts from fat tissue are associated with widespread inflammation, which is encountered as another negative factor. In recent studies, many studies have aimed to define the abdominal fat distribution properties of obese people (visceral and subcutaneous).

Sempere et al. [30] evaluated waist circumference (WC) and BMI as markers of abdominal fat distribution and found that increased WC (RR: 4.65, 95% CI: 1.17-18.5) and BMI (RR: 2.06, 95% CI: 0.99-4.19) increased the risk of severe AP development. Based on this evidence, abdominal obesity appears to be more relevant in predicting severe AP than general obesity. A study in Japan identified 85 cm waist circumference for men and 90 cm waist circumference for women as equivalent to a 100 cm2 VFA cut-off point as a marker of disorder risk associated with obesity [31]. Similarly, a Japanese study including 12,443 subjects in visceral fat accumulation and coronary artery disease research (VACATION-J) found that major cardiovascular events were associated with increased VFA; however, no correlation with SFA was found.

A 62-patient study by O’Leary et al. [32] showed that increased abdominal VFA level measured with abdominal CT was associated with development of severe AP and increased risk of systemic complications. A study published by Xie et al. in 2019 revealed that increased abdominal VFA level and VTR were closely associated with worsening AP [33]. Similarly, in our study, the increases in VFA level and VTR were associated with high AP clinical scores. Additionally, in our study the measurements for fat tissue area were found to be higher than values in the literature. This situation is considered to be associated with the fact that the majority of the mentioned studies concerned East Asian populations. Similar studies performed in our country will reveal the abdominal fat distribution features of people living in this region.

Limitations

This study has important limitations. The first is that our study is a single-center study. Our study was performed in a single province at the only university hospital in the provincial center, which significantly reduces the generalizability of the study. Since the inclusion of patients with a diagnosis of severe AP that we planned before our study could not be achieved, we could only evaluate mild and moderate AP patients. Additionally, fat distribution measurements were retrospectively made on noncontrast enhanced abdomen CT taken for AP diagnosis for patients in the emergency service, and we may not have accessed optimal measurement results due to differences in technique. Due to our study being retrospective, BMI measurements of patients could not be recorded and patients could not be grouped.

Conclusions

In conclusion, patients with AP diagnosis and abdominal CT with increased VFA and VTR had increased mean AP clinical scores, with no significant correlation identified in terms of local/systemic complication development. There is a need for studies on this topic with larger patient groups assessing the abdominal fat distribution in groups comprising patients with different BMI values. Abdominal CT measurement is a useful, repeatable method providing objective results. We believe this method will provide significant contributions to developments in AP diagnosis and treatment.

Disclosure

The authors declare no conflict of interest.

References

1 

Murata A, Matsuda S, Mayumi T, et al. Multivariate analysis of factors influencing medical costs of acute pancreatitis hospitalizations based on a national administrative database. Dig Liver Dis 2012; 44: 143-148.

2 

Wyncoll DL. The management of severe acute necrotising pancreatitis: an evidence-based review of the literature. Intensive Care Med 1999; 25: 146-156.

3 

Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012; 143: 1179-1187.e3.

4 

Hammad AY, Ditillo M, Castanon L. Pancreatitis. Surg Clin North Am 2018; 98: 895-913.

5 

Chandra S, Murali A, Bansal R, et al. The Bedside Index for Severity in Acute Pancreatitis: a systematic review of prospective studies to determine predictive performance. J Community Hosp Intern Med Perspect 2017; 7: 208-213.

6 

Wilson C, Heath DI, Imrie CW. Prediction of outcome in acute pancreatitis: a comparative study of APACHE II, clinical assessment and multiple factor scoring systems. Br J Surg 1990; 77: 1260-1264.

7 

Choi HW, Park HJ, Choi SY, et al. Early prediction of the severity of acute pancreatitis using radiologic and clinical scoring systems with classification tree analysis. AJR Am J Roentgenol 2018; 211: 1035-1043.

8 

Kuo DC, Rider AC, Estrada P, et al. Acute pancreatitis: What’s the score? J Emerg Med 2015; 48: 762-770.

9 

Imrie CW. Prognostic indicators in acute pancreatitis. Can J Gastroenterol 2003; 17: 325-328.

10 

Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis 2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013; 62: 102-111.

11 

Buter A, Imrie CW, Carter CR, et al. Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. Br J Surg 2002; 89: 298-302.

12 

Carioca AL, Jozala DR, de Bem LO, da Silva Rodrigues JM. Severity assessment of acute pancreatitis: applying Marshall scoring system. Rev Col Bras Cir 2015; 42: 325-327.

13 

IAP/APA evidence-based guidelines for the management of acute pancreatitis. Pancreatology 2013; 13 (4 Suppl 2): e1-15.

14 

Natu A, Stevens T, Kang L, et al. Visceral adiposity predicts severity of acute pancreatitis. Pancreas 2017; 46: 776-781.

15 

Adiamah A, Psaltis E, Crook M, Lobo DN. A systematic review of the epidemiology, pathophysiology and current management of hyperlipidaemic pancreatitis. Clin Nutr 2018; 37: 1810-1822.

16 

Huang J, Qu HP, Zheng YF, et al. The revised Atlanta criteria 2012 altered the classification, severity assessment and management of acute pancreatitis. Hepatobiliary Pancreat Dis Int 2016; 15: 310-315.

17 

Sureka B, Bansal K, Patidar Y, Arora A. Imaging lexicon for acute pancreatitis: 2012 Atlanta Classification revisited. Gastroenterol Rep (Oxf) 2016; 4: 16-23.

18 

Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990; 174: 331-336.

19 

Garg SK, Sarvepalli S, Campbell JP, et al. Incidence, admission rates, and predictors, and economic burden of adult emergency visits for acute pancreatitis: data from the national emergency department sample, 2006 to 2012. J Clin Gastroenterol 2019; 53: 220-225.

20 

Sundararajan K, Schoeman T, Hughes L, et al. Predictors and outcomes of acute pancreatitis in critically ill patients presenting to the emergency department of a tertiary referral centre in Australia. Emerg Med Australas 2017; 29: 184-191.

21 

Gardner TB, Vege SS, Chari ST, et al. The effect of age on hospital outcomes in severe acute pancreatitis. Pancreatology 2008; 8: 265-270.

22 

Wang X, Xu Y, Qiao Y, et al. An evidence-based proposal for predicting organ failure in severe acute pancreatitis. Pancreas 2013; 42: 1255-1261.

23 

Martínez J, Johnson CD, Sánchez-Payá J, et al. Obesity is a definitive risk factor of severity and mortality in acute pancreatitis: An updated meta-analysis. Pancreatology 2006; 6: 206-209.

24 

de Heredia FP, Gómez-Martínez S, Marcos A. Obesity, inflammation and the immune system. Proc Nutr Soc 2012; 71: 332-338.

25 

Hong S, Qiwen B, Ying J, et al. Body mass index and the risk and prognosis of acute pancreatitis: a meta-analysis. Eur J Gastroenterol Hepatol 2011; 23: 1136-1143.

26 

Fei Y, Gao K, Tu J, et al. Predicting and evaluation the severity in acute pancreatitis using a new modeling built on body mass index and intra-abdominal pressure. Am J Surg 2018; 216: 304-309.

27 

Katuchova J, Bober J, Harbulak P, et al. Obesity as a risk factor for severe acute pancreatitis patients. Wien Klin Wochenschr 2014; 126: 223-227.

28 

Taguchi M, Kubo T, Yamamoto M, et al. Body mass index influences the outcome of acute pancreatitis: an analysis based on the Japanese administrative database. Pancreas 2014; 43: 863-866.

29 

Krishna SG, Hinton A, Oza V, et al. Morbid obesity is associated with adverse clinical outcomes in acute pancreatitis: a propensity-matched study. Am J Gastroenterol 2015; 110: 1608-1619.

30 

Sempere L, Martinez J, de Madaria E, et al. Obesity and fat distribution imply a greater systemic inflammatory response and a worse prognosis in acute pancreatitis. Pancreatology 2008; 8: 257-264.

31 

The Examination Committee of Criter. New Criteria for ‘Obesity Disease’ in Japan. Circ J 2002; 66: 987-992.

32 

O’Leary DP, O’Neill D, McLaughlin P, et al. Effects of abdominal fat distribution parameters on severity of acute pancreatitis. World J Surg 2012; 36: 1679-1685.

33 

Xie J, Xu L, Pan Y, et al. Impact of visceral adiposity on severity of acute pancreatitis: a propensity score–matched analysis. BMC Gastroenterol 2019; 19: 87.

Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
 
Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.